Advanced search
Publication Cover
Bioanalysis Volume 5, 2013 - Issue 22
Submit an article Journal homepage
464
Views
0
CrossRef citations to date
0
Altmetric
Review

The Challenges of LC–MS/MS Analysis of Opiates and Opioids in Urine

Deborah FrenchUniversity of California San Francisco, 185 Berry Street, Suite 290, San Francisco, CA94107, USA. [email protected]
Pages 2803-2820 | Published online: 21 Nov 2013

References

  • Matthes HW , MaldonadoR, SimoninFet al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid receptor gene. Nature383, 819–823 (1996).
  • Fricchione GL , MendozaA, StefanoGB. Morphine and its psychiatric implications. Adv. Neuroimmunol. 4(2), 117–131 (1994).
  • Pattinson KT . Opioids and the control of respiration. Br. J. Anaesth. 100(6), 747–758 (2008).
  • Manara L , BianchiG, FerrettiP, TavaniA. Inhibition of gastrointestinal transit by morphine in rats results from direct drug action on gut opioid sites. J. Pharmacol. Exp. Ther. 237(3), 945–949 (1986).
  • Feng Y , HeX, YangY, ChaoD, LazarusLH, XiaY. Current research on opioid receptor function. Curr. Drug Targets13(2), 230–246 (2012).
  • Boyer EW . Management of opioid analgesic overdose. N. Engl. J. Med. 367(2), 146–155 (2012).
  • Manchikanti L , HelmS2nd, FellowsBet al. Opioid epidemic in the United States. Pain Physician15, ES9–ES38 (2012).
  • Manchikanti L , SinghA. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse and non-medical use of opioids. Pain Physician11, S63–S88 (2008).
  • Bronstein AC , SpykerDA, CantilenaLRJr. Rumack BH, Dart RC. 2011 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th annual report. Clin. Toxicol. Phila)50(10), 911–1164 (2012).
  • Cunha-Oliveira T , RegoAC, OliveiraCR. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res. Rev. 58, 192–208 (2008).
  • Karow A , VertheinU, KrauszM, SchäferI. Association of personality disorders, family conflicts and treatment with quality of life in opiate addiction. Eur. Addict. Res. 14, 38–46 (2008).
  • Ivanov IS , Schulz,KP, PalmeroRC, NewcornJH. Neurobiology and evidence-based biological treatments for substance abuse disorders. CNS Spectr. 11(11), 864–877 (2006).
  • Birnbaum HG , WhiteAG, ReynoldsJLet al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001. A societal perspective. Clin. J. Pain22, 667–676 (2006).
  • Rook EJ , HuitemaADR, van den Brink W, van Ree JM, Beijnen JH. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr. Clin. Pharmacol. 1(1), 109–118 (2006).
  • Baselt RC . Disposition of Toxic Drugs and Chemicals in Man. (7th Edition). Biomedical Publications, Foster City, CA, USA (2004).
  • Milne RW , NationRL, SomogyiAA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab. Rev. 28(3), 345–472 (1996).
  • Coffman BL , RiosGR, KingCD, TephlyTR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 25(1), 1–4 (1997).
  • Coffman BL , KingCD, RiosGR, TephlyTR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 26(1), 73–77 (1998).
  • Paul D , StandiferKM, InturrisiCE, PasternakGW. Pharmacological characterization of morphine-6-beta-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther. 251(2), 477–483 (1989).
  • Yeh SY , GorodetzkyCW, KrebsHA. Isolation and identification of morphine 3- and 6-glucuronides, morphine-3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans. J. Pharm. Sci. 66(9), 1288–1293 (1977).
  • Projean D , Morin P-E, Tu TM, Ducharme J. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica33(8), 841–854 (2003).
  • Mannering GJ , DixonAC, BakerEM 3rd, Asami T. The in vivo liberation of morphine from codeine in man. J. Pharmacol. Exp. Ther. 111(2), 142–146 (1954).
  • Nomof N , ElliottHW, ParkerKD. Actions and metabolism of codeine (methylmorphine) administration by continuous intravenous infusion to humans. Clin. Toxicol. 11(5), 517–529 (1977).
  • Srinivasan V , WielboD, SimpkinsJ, KarlixJ, SloanK, TebbettI. Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide. Pharm. Res. 13(2), 296–300 (1996).
  • Cone EJ , DarwinWD, GorodetzkyCW. Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites. J. Pharm. Pharmacol. 31, 314–317 (1979).
  • Cone EJ , HeitHA, YaleHC, GourlayD. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J. Anal. Toxicol. 30(1), 1–6 (2006).
  • Oyler JM , ConeEJ, HosephREJr, HuestisMA. Identification of hydrocodone in human urine following controlled codeine administration. J. Anal. Toxicol. 24(7), 530–535 (2000).
  • Cone EJ , DarwinWD, GorodetzkyCW, TanT. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit and dog. Drug Metab. Dispos. 6(4), 488–493 (1978).
  • Otton SV , SchadelM, CheungSW, KaplanHI, BustoUE, SellersEM. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 54(5), 463–472 (1993).
  • Valtier S , BebartaVS. Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers. J. Anal. Toxicol. 36(7), 507–514 (2012).
  • Baselt RC , StewartCB. Determination of oxycodone and a major metabolite in urine by electron-capture GLC. J. Anal. Toxicol. 2(3), 107–109 (1978).
  • Lalovic B , KharaschE, HofferC, RislerL, Liu-Chen L-Y, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. 79(5), 461–479 (2006).
  • Cone EJ , HeltsleyR, BlackDL, MitchellJM, LoDicoCP, FlegelRR. Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration. J. Anal. Toxicol. 37(5), 255–264 (2013).
  • Cone EJ , DarwinWD, BuchwaldWF, GorodetzkyCW. Oxymorphone metabolism and urinary excretion in human, rat, guinea-pig, rabbit, and dog. Drug Metab. Dispos. 11(5), 446–450 (1983).
  • Labroo RB , PaineMF, ThummelKE, KharaschED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy and drug interactions. Drug Metab. Dispos. 25(9), 1072–1080 (1997).
  • Moody DE . Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. Expert Opin. Drug Metab. Toxicol. 9(6), 675–697 (2013).
  • Yang A , ArfkenCL, Johanson C-E. Steps physicians report taking to reduce diversion of buprenorphine. Am. J. Addict. 22(3), 184–187 (2013).
  • Marsch LA , StephensMAC, MudricT, StrainEC, BigelowGE, JohnsonRE. Predictors of outcome in LAAM, buprenorphine and methadone treatment for opioid dependence. Exp. Clin. Psychopharmacol. 13(4), 293–302 (2005).
  • Manchikanti L , ManchukondaR, PampatiVet al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 9(2), 123–129 (2006).
  • Katz N , FanciulloGJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin. J. Pain18(4 Suppl.), S76–S82 (2002).
  • Reisfield GM , SalazarE, BertholfRL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann. Clin. Lab. Sci. 37(4), 301–314 (2007).
  • Reisfield GM , GoldbergerBA, BertholfRL. ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing. Bioanalysis1(5), 937–952 (2009).
  • Wu AHB , McKayC, BroussardLAet al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin. Chem. 49(3), 357–379 (2003).
  • Villena VP . Beating the system: a study of a creatinine assay and its efficacy in authenticating human urine specimens. J. Anal. Toxicol. 34(1), 39–44 (2010).
  • Cook JD , CaplanYH, LoDicoCP, BushDM. The characterization of human urine for specimen validity determination in workplace drug testing: a review. J. Anal. Toxicol. 24(7), 579–588 (2000).
  • Fox EJ , TwiggerS, AllenKR. Criteria for opiate identification using liquid chromatography linked to tandem mass spectrometry: problems in routine practice. Ann. Clin. Biochem. 46(Pt 1), 50–57 (2009).
  • French D , WuAHB, LynchK. Hydrophilic interaction LC–MS/MS analysis of opioids in urine: significance of glucuronide metabolites. Bioanalysis3(23), 2603–2612 (2011).
  • Dickerson JA , LahaTJ, PaganoMB, O’DonnellBR, HoofnagleAN. Improved detection of opioid use in chronic pain patients through monitoring of opioid glucuronides in urine. J. Anal. Toxicol. 36(8), 541–547 (2012).
  • Annesley TM . Ion suppression in mass spectrometry. Clin. Chem. 49(7), 1041–1044 (2003).
  • Matuszewski BK , ConstanzerML, Chavez-EngCM. Strategies for the assessment of matrix effect matrix effect in quantitative bioanalytical methods based on HPLC–MS/MS. Anal. Chem. 75(13), 3019–3030 (2003).
  • Dams R , HuestisMA, LambertWE, MurphyCM. Matrix effect in bioanalysis of illicit drugs with LC–MS/MS: influence of ionization type, sample preparation and biofluid. J. Am. Soc. Mass Spectrom. 14(11), 1290–1294 (2003).
  • Goldberger BA , ConeEJ. Confirmatory tests for drugs in the workplace by gas chromatography–mass spectrometry. J. Chromatogr. A674(1–2), 73–86 (1994).
  • Marquet P , LachâtreG. Liquid chromatography–mass spectrometry: potential in forensic and clinical toxicology. J. Chromatogr. B Biomed. Sci. Appl. 733(1–2), 93–118 (1999).
  • Heltsley R , ZichtermanA, BlackDLet al. Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites. J. Anal. Toxicol. 34, 32–38 (2010).
  • Cone EJ , ZichtermanA, HeltsleyRet al. Urine testing for norcodeine, norhydrodone, and noroxycodone facilitates interpretation and reduces false negatives. Forensic Sci. Int. 198(1), 58–61 (2010).
  • Concheiro M , CastroAD, QuintelaO, CruzA, López-RivadullaM. Determination of illicit drugs and their metabolites in human urine by liquid chromatography tandem mass spectrometry including relative ion intensity criteria. J. Anal. Toxicol. 31(9), 573–580 (2007).
  • Fitzgerald RL , GriffinTL, Yun Y-Met al. Dilute and shoot: analysis of drugs of abuse using selected reaction monitoring for quantification and full scan product ion spectra for identification. J. Anal. Toxicol. 36, 106–111 (2012).
  • Dams R , MurphyCM, LambertWE, HuestisMA. Urine drug testing for opioids, cocaine and metabolites by direct injection liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17(14), 1665–1670 (2003).
  • Shakleya DM , DamsR, ChooRE, JonesH, HuestisMA. Simultaneous liquid chromatography–mass spectrometry quantification of urinary opiates, cocaine, and metabolites in opiate-dependent pregnant women in methadone-maintenance treatment. J. Anal. Toxicol. 34(1), 17–25 (2010).
  • Dowling G , ReganL, TierneyJ, NangleM. A hybrid liquid chromatography–mass spectrometry strategy in a forensic laboratory for opioid, cocaine and amphetamine classes in human urine using a hybrid linear ion trap-triple quadrupole mass spectrometer. J. Chromatogr. A1217(44), 6857–6866 (2010).
  • Edinboro LE , BackerRC, PoklisA. Direct ana¬lysis of opiates in urine by liquid chromatography–tandem mass spectrometry. J. Anal. Toxicol. 29(7), 704–710 (2005).
  • Thörngren J-O . Östervall F, Garle M. A high-throughput multicomponent screening method for diuretics, masking agents, central nervous system (CNS) stimulants and opiates in human urine by UPLC–MS/MS. J. Mass Spectrom. 43(7), 980–992 (2008).
  • Gustavsson E , AnderssonM, StephansonN, BeckO. Validation of direct injection electrospray LC–MS/MS for confirmation of opiates in urine drug testing. J. Mass Spectrom. 42(7), 881–889 (2007).
  • Bonfiglio R , KingRC, OlahTV, MerkleK. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 13(12), 1175–1185 (1999).
  • Murphy CM , HuestisMA. LC-ESI-MS/MS ana¬lysis for the quantification of morphine, codeine, morphine-3-β-D-glucuronide, morphine-6-β-D--glucuronide, and codeine-6-β-D--glucuronide in human urine. J. Mass Spectrom. 40, 1412–1416 (2005).
  • Coles R , KushnirMM, NelsonGJ, McMillinGA, UrryFM. Simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone and 6-acetylmorphine in urine, serum, plasma, whole blood, and meconium by LC–MS-MS. J. Anal. Toxicol. 31(1), 1–10 (2007).
  • Berg T , LundanesE, ChristophersenAS, StandDH. Determination of opiates and cocaine in urine by high pH mobile phase reversed phase UPLC–MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(4), 421–432 (2009).
  • McMillin GA , DavisR, CarlisleH, ClarkC, MarinSJ, MoodyDE. Patterns of free (unconjugated) buprenorphine, norbuprenorphine and their glucuronides in urine using liquid chromatography–tandem mass spectrometry. J. Anal. Toxicol. 36(2), 81–87 (2012).
  • Musshoff F , TrafkowskiJ, KuepperU, MadeaB. An automated and fully validated LC–MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites. J. Mass Spectrom. 41(5), 633–640 (2006).
  • Maralikova B , WeinmannW. Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography–tandem mass spectrometry with respect to criteria for compound identification. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 811(1), 21–30 (2004).
  • de Jager AD , BaileyNL. Online extraction LC–MS/MS method for simultaneous quantitative confirmation of urine drugs of abuse and metabolites: amphetamines, opiates, cocaine, cannabis, benzodiazepines and methadone. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879(29), 2642–2652 (2011).
  • Liu A-C . Lin T-Y, Su L-W, Fuh M-R. Online solid-phase extraction liquid chromatography–electrospray-tandem mass spectrometry analysis of buprenorphine and three metabolites in human urine. Talanta75(1), 198–204 (2008).
  • Schaefer N , PetersB, SchmidtP, EwaldAH. Development and validation of twoLC–MS/MS methods for the detection and quantification of amphetamines, designer amphetamines, benzoylecgonine, benzodiazepines, opiates, and opioids in urine using turbulent flow chromatography. Anal. Bioanal. Chem. 405(1), 247–258 (2013).
  • Hemström P , IrqumK. Hydrophilic interaction chromatography. J. Sep. Sci. 29(12), 1784–1821 (2006).
  • Brown PR , KrstulovicAM. Practical aspects of reversed-phase liquid chromatography applied to biochemical and biomedical research. Anal. Biochem. 99(1), 1–21 (1979).
  • Jian W , EdomRW, XuY, WengN. Recent advances in application of hydrophilic interaction chromatography for quantitative analysis. J. Sep. Sci. 33, 681–697 (2010).
  • Jian W , XuY, EdomRW, WengN. Analysis of polar metabolites by hydrophilic interaction chromatography–MS/MS. Bioanalysis3(8), 899–912 (2011).
  • Cone EJ , GorodetzkyCW, YousefnejadD, BuchwaldWF, JohnsonRE. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12(5), 577–581 (1984).
  • Huang M-Z . Yuan C-H, Cheng S-C, Cho Y-T, Shiea J. Ambient ionization mass spectrometry. Annu. Rev. Anal. Chem. 3, 43–65 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.